Connect Portal

  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
  • About
    • About
    • Leadership
    • News
    • Careers
    • Forms
    • Contact

OmniSeq is excited to announce it is now part of Labcorp!

by Christina Black | Jul 29, 2021 | News

Inflammation Signature May Predict Checkpoint Inhibitor Response in Gastroesophageal Cancer, Study Finds

by Christina Black | Jul 22, 2021 | News

Labcorp and OmniSeq Launch Insight, Next-Generation Sequencing Platform to Advance Precision Oncology

by Christina Black | Jun 10, 2021 | News

OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling Test

by Christina Black | Apr 27, 2021 | News

Cancer-testis antigen detection by targeted RNA sequencing

by OmniSeq Staff | Dec 3, 2020 | News

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...

Cancer testis antigen co-expression landscape in solid tumors

by OmniSeq Staff | Dec 3, 2020 | News

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...
« Older Entries

Follow Us on Twitter

OmniSeq Follow

Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek

Avatar
Avatar OmniSeq @omniseq ·
25 Jan

OmniSeq® is now part of Labcorp. Be sure to follow Labcorp to stay up-to-date on the latest #oncology updates. We look forward to providing timely and relevant information about how we are driving precision cancer care forward: https://bit.ly/3BdrZUu

Reply on Twitter 1618262421751173121 Retweet on Twitter 1618262421751173121 Like on Twitter 1618262421751173121 1 Twitter 1618262421751173121
Avatar OmniSeq @omniseq ·
4 Nov

This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S

Reply on Twitter 1588584498606014465 Retweet on Twitter 1588584498606014465 Like on Twitter 1588584498606014465 Twitter 1588584498606014465
Avatar OmniSeq @omniseq ·
3 Jun

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine

Reply on Twitter 1532751537994342401 Retweet on Twitter 1532751537994342401 Like on Twitter 1532751537994342401 5 Twitter 1532751537994342401
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
#2561-Developmental Therapeutics—Immunotherapy
Sunday, June 5, 8-11:00 AM CDT

Reply on Twitter 1530217104867196928 Retweet on Twitter 1530217104867196928 Like on Twitter 1530217104867196928 3 Twitter 1530217104867196928
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530216482998734850 Retweet on Twitter 1530216482998734850 Like on Twitter 1530216482998734850 3 Twitter 1530216482998734850
Load More...

  • Facebook
  • Twitter
©2023 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .